A5025462204- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Computational Drug Discovery Methods
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Virus-based gene therapy research
- Meningioma and schwannoma management
- Cancer Treatment and Pharmacology
- Nanoplatforms for cancer theranostics
- Mental Health Research Topics
- Immunotherapy and Immune Responses
- Prostate Cancer Treatment and Research
- Inflammatory Biomarkers in Disease Prognosis
- Mathematical Biology Tumor Growth
- Immune cells in cancer
- Bone and Joint Diseases
- Qualitative Comparative Analysis Research
- Protein Degradation and Inhibitors
- Meta-analysis and systematic reviews
Center for Neuro-Oncology
2020-2025
Dana-Farber Cancer Institute
2020-2025
Harvard University
2020-2025
Brigham and Women's Hospital
2020-2024
Boston University
2023
Dana-Farber Brigham Cancer Center
2021-2023
Massachusetts General Hospital
2020-2022
The University of Texas MD Anderson Cancer Center
2019
American University of Beirut Medical Center
2017
PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade (RANO-LGG) were developed to improve reliability of response assessment glioma trials. Over time, some limitations these identified, challenges emerged regarding integrating features the modified RANO (mRANO) or immunotherapy (iRANO) criteria. METHODS Informed by data from studies evaluating different criteria, updates are proposed (RANO 2.0). RESULTS We recommend a standard set...
PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria are widely used high-grade glioma clinical trials. We compared the RANO with updated modifications (modified [mRANO] and immunotherapy [iRANO] criteria) patients newly diagnosed glioblastoma (nGBM) recurrent GBM (rGBM) to evaluate performance of each set inform development planned 2.0 update. MATERIALS AND METHODS Evaluation tumor measurements fluid-attenuated inversion recovery (FLAIR) sequences were performed by blinded...
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, CD8 + T cell blocking studies mice, demonstrated this results from an inflammatory response following antiprogrammed death 1 (PD1) antibody treatment disrupts the blood–tumor barrier. Used lieu of immunosuppressive corticosteroids, angiotensin receptor blocker...
Abstract Background With the significant shift in classification, risk stratification, and standards of care for gliomas, we sought to understand how overall survival patients with these tumors is impacted by molecular features, clinical metrics, treatment received. Methods We assembled a cohort histopathologically diagnosed glioma from The Cancer Genome Atlas (TCGA), Project Genomics Evidence Neoplasia Information Exchange, Dana-Farber Institute/Brigham Women’s Hospital. This incorporated...
In CheckMate 204, nivolumab + ipilimumab showed high intracranial (IC) objective response rates (icORRs) in patients with melanoma brain metastases (MBMs). Using icORR as a surrogate for overall survival (OS) has prompted use of alternate criteria. To set the stage harmonized MBM trials, aim this exploratory analysis was to determine using several criteria and examine correlations survival.
Abstract Background Patients with glioblastoma experience high physical and psychosocial symptom burden. Poor social relationships have been shown to increase the risk of neurologic illnesses decline, conversely, strong personal networks (PSN) reduce mortality improve quality life. The aim this pilot study is determine feasibility measuring PSN in patients. Methods We recruited 25 adult patients between initial diagnosis first cycle adjuvant chemotherapy from March September 2023 outpatient...
Adverse clinical events cause significant morbidity in patients with GBM (GBM). We examined whether genomic alterations were associated AE (AE) GBM.
Abstract Background Targeted gene NGS testing is available through many academic institutions and commercial entities increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating results management GBM patients at a trials-focused center. Methods We identified 1011 consecutive adult with pathologically confirmed (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer...
Viroimmunotherapy is evolving as a strong alternative for the standard treatment of malignant gliomas. Promising results from recent clinical trial testing anticancer effect Delta-24-RGD in patients with glioblastoma suggested induction antitumoral immunity after viral administration. To further enhance anti-glioma immune effect, we have armed costimulatory ligand GITRL (Delta-24-GREAT [Glucocorticoid Receptor Enhanced Activity T cells]).We tested infectivity and replication Delta-24-GREAT,...
2017 Background: Response Assessment in Neuro-Oncology (RANO) criteria for high-grade and low-grade glioma (HGG LGG) were developed to improve reliability of response assessment trials. Several limitations the original RANO have been reported. Methods: To address criteria, a large cohort patients with newly diagnosed recurrent glioblastoma evaluated comparing RANO-HGG modified (mRANO) immunotherapy (iRANO) inform following proposed updates (RANO 2.0). Results: Based on 2021 WHO...
Abstract Background Glioblastomas comprise heterogeneous cell populations with dynamic, bidirectional plasticity between treatment-resistant stem-like and treatment-sensitive differentiated states, treatment influencing this process. However, current protocols do not account for plasticity. Previously, we generated a mathematical model based on preclinical experiments to describe process optimize radiation therapy fractionation schedule that substantially increased survival relative standard...
Abstract Background Glioblastoma (GBM) patients are treated with radiation therapy, chemotherapy, and corticosteroids, which can cause myelosuppression. To understand the relative prognostic utility of blood-based biomarkers in GBM its implications for clinical trial design, we examined incidence, predictors, value lymphopenia, neutrophil-to-lymphocyte ratio (NLR), platelet count during chemoradiation (CRT) recurrence. Methods This cohort study included 764 newly diagnosed glioblastoma from...
Abstract Background Burnout is a syndrome characterized by emotional exhaustion, depersonalization, and reduced sense of accomplishment, which commonly arises from chronic workplace stress in the medical field. Given higher risk burnout younger age groups reported some studies, Society for Neuro-Oncology (SNO) Young Investigator (YI) Wellness Committees combined efforts to examine SNO YI membership better understand address their needs. Methods We distributed an anonymous online survey...
2016 Background: Ibudilast is a selective inhibitor of macrophage inhibitory factor (MIF) activity, which upregulated in GBM and promotes stem cell growth. It also disrupts the interaction between MIF CD74. When combined with temozolomide (TMZ) preclinical studies, it attenuates immunosuppressive properties myeloid-derived suppressor cells enhances tumor regression. This phase 1b/2a single-center, open-label, dose escalation study evaluating safety, tolerability, efficacy combination TMZ...
Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of trials remains undefined. This study describes the real-world utilization mutant IDH1 inhibitor (IDHi), ivosidenib, patients with glioma. We retrospectively reviewed and radiographic data from treated ivosidenib monotherapy 2020 to 2024 at Dana-Farber Cancer Institute Massachusetts General Hospital. cohort included 74...
Pattern reversal visual evoked potential (PRVEP) is an electrophysiological test for evaluating the pathway. This study measured changes in latencies and amplitudes of PRVEP with age gender normal subjects.Healthy participants (n=81; 162 total eyes), between ages 20 92 years were recruited study. Stimulation was performed monocularly a high-contrast (>50%) black-white checkerboard pattern check size 30° at rate 2 Hz, band-pass 1-100 sweep 250 msec average 150 stimulations dark room. Mean...